Literature DB >> 15271391

Animal models of chronic myelogenous leukemia.

Robert L Ilaria1.   

Abstract

Of the current mouse chronic myelogenous leukemia (CML) models,the murine bone marrow (BM) transduction and transplantation model most efficiently mimics many of the central features of human CML. In this model, lethally irradiated mice are reconstituted with primary murine BM cells transduced with a P210BCR/ABL retrovirus. All recipient mice develop a fatal peripheral blood and BM granulocytosis and splenomegaly, a disease termed the murine CML-like myeloproliferative disorder. This model has been used to establish the causative role of Bcr/Abl in CML, identify those signaling pathways and regions of Bcr/Abl critical for leukemogenesis, and explore the limitations of targeted CML therapy. Future refinements in this CML mouse model will make it a more effective tool for studying imatinib-resistant CML, reproducing chronic- and blastic-phase human CML, and performing CML progenitor studies.

Entities:  

Mesh:

Year:  2004        PMID: 15271391     DOI: 10.1016/j.hoc.2004.03.003

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  8 in total

1.  Oral administration of imatinib to P230 BCR/ABL-expressing transgenic mice changes clones with high BCR/ABL complementary DNA expression into those with low expression.

Authors:  Mitsuharu Inami; Koiti Inokuchi; Hiroki Yamaguchi; Kazutaka Nakayama; Ayako Watanabe; Naoya Uchida; Sakae Tanosaki; Kazuo Dan
Journal:  Int J Hematol       Date:  2006-11       Impact factor: 2.490

2.  Galectin-3 (Gal-3) induced by leukemia microenvironment promotes drug resistance and bone marrow lodgment in chronic myelogenous leukemia.

Authors:  Mio Yamamoto-Sugitani; Junya Kuroda; Eishi Ashihara; Hisao Nagoshi; Tsutomu Kobayashi; Yosuke Matsumoto; Nana Sasaki; Yuji Shimura; Miki Kiyota; Ryuko Nakayama; Kenichi Akaji; Tomohiko Taki; Nobuhiko Uoshima; Yutaka Kobayashi; Shigeo Horiike; Taira Maekawa; Masafumi Taniwaki
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-10       Impact factor: 11.205

3.  Gambogic acid induces apoptosis in imatinib-resistant chronic myeloid leukemia cells via inducing proteasome inhibition and caspase-dependent Bcr-Abl downregulation.

Authors:  Xianping Shi; Xin Chen; Xiaofen Li; Xiaoying Lan; Chong Zhao; Shouting Liu; Hongbiao Huang; Ningning Liu; Siyan Liao; Wenbin Song; Ping Zhou; Shunqing Wang; Li Xu; Xuejun Wang; Q Ping Dou; Jinbao Liu
Journal:  Clin Cancer Res       Date:  2013-12-12       Impact factor: 12.531

4.  PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia.

Authors:  Nicholas C Wolff; Darren R Veach; William P Tong; William G Bornmann; Bayard Clarkson; Robert L Ilaria
Journal:  Blood       Date:  2005-01-18       Impact factor: 22.113

Review 5.  In Vitro and In Vivo Modeling of Normal and Leukemic Bone Marrow Niches: Cellular Senescence Contribution to Leukemia Induction and Progression.

Authors:  Myriam Janeth Salazar-Terreros; Jean-Paul Vernot
Journal:  Int J Mol Sci       Date:  2022-07-01       Impact factor: 6.208

6.  STAT5 signaling is required for the efficient induction and maintenance of CML in mice.

Authors:  Dan Ye; Nicholas Wolff; Li Li; Shumin Zhang; Robert L Ilaria
Journal:  Blood       Date:  2006-03-07       Impact factor: 22.113

7.  Expression and function of PML-RARA in the hematopoietic progenitor cells of Ctsg-PML-RARA mice.

Authors:  Lukas D Wartman; John S Welch; Geoffrey L Uy; Jeffery M Klco; Tamara Lamprecht; Nobish Varghese; Rakesh Nagarajan; Timothy J Ley
Journal:  PLoS One       Date:  2012-10-08       Impact factor: 3.240

8.  A single-tube allele specific-polymerase chain reaction to detect T315I resistant mutation in chronic myeloid leukemia patients.

Authors:  Wanwisa Wongboonma; Wanna Thongnoppakhun; Chirayu U Auewarakul
Journal:  J Hematol Oncol       Date:  2011-02-08       Impact factor: 17.388

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.